TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: post-OLT tumor recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Patient preferences for denture attachments
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: exercise test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health-related quality of life (HRQoL) measured by 15D scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Scores on the State-Trait Anxiety Inventory (STAI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Scores on the Pittsburgh Sleep Quality Index
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: behavioural treatment outcome in OCD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PEDsQL total scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Range of movement and functional scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3 oesophagitis
Endpoint domain: Adverse events/effects
Primary endpoint: prolonged duration of analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LPV AUC(0,24 h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: concentration at the end of the dosing interval (C(24 h))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean of the maximum intima-media thicknesses (IMT) progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intrusive thoughts frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Irrational interpretations frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in autonomy-based self-care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in problematic outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of retrieved lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Incidence of postoperative cognitive dysfunction
Endpoint domain: Adverse events/effects
Primary endpoint: Recognition memory of deeply encoded words
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: vocational outcomes
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: two‐yr patient survival
Endpoint domain: Mortality/survival
Primary endpoint: two‐yr graft survival
Endpoint domain: Mortality/survival
Primary endpoint: Concentration disturbances
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Intra-abdominal complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Multiple organ failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Base width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mass distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinically significant CMV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Acceptability of alcohol enquiry
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall severity, strain, loudness, and instability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fundamental frequency (F0) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: F0 variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum albumin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Lp(a) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 1-year cardiovascular events (cardiovascular death, myocardial infarction, or stroke)
Endpoint domain: Mortality/survival
Primary endpoint: effectiveness of weight-loss tools
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: effectiveness of group-based weight-loss support program
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment-free interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in pain unpleasantness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean percent change in total lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: percentage of subjects rated as treatment success based on IGA
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: percentage of subjects rated as treatment success based on SGA
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Knowledge of side effects of prostaglandin
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Understanding of time to birth
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: hip measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breathing comfort
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Completion of therapy without developing a documented or suspected fungal infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Apoptosis of gastric carcinoma cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: disutility measured using EQ‐5D‐3L
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: impaired global health status measured using EORTC QLQ‐C30
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Frailty Index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hand grip test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival rate of root-treated upper central incisors
Endpoint domain: Mortality/survival
Primary endpoint: fracture load including technical failures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxycodone AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxycodone elimination half-life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fastest sprint time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response for nocturnal paresthesias
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of neonatal hypothermia on arrival to the admitting nursery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of moderate to severe hypothermia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neonatal temperature in the operating room immediately following delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ghrelin responses to glucose load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute manic episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute depressive episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: related hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Pain magnitude reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in primary end point
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: plasma BDNF concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in pill or condom mishaps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean laxity assessed using KT‐1000 arthrometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: integrity of the ACL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10- and 20-year survival rates
Endpoint domain: Mortality/survival
Primary endpoint: liver disease-related deaths
Endpoint domain: Mortality/survival
Primary endpoint: cumulative morphine dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Karolinska score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cumulative incidence of moderate depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biopsy proven acute rejection (BPAR) at 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Stiffness index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amplitude-dependent speed of sound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cardiac fitness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Functional Assessment of Cancer Therapy‐Prostate (FACT‐P)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Bishop scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportions of women entering active labor or delivering within 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social interaction
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Large positive or negative interest fluctuations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Effect-site concentration for sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in TC/HDLC ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Increase in IP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic endotoxemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of BT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participation in competitive employment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Total lymphocyte count on the third postoperative day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD4/CD8 ratio from day 3 to day 7 postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma tumor necrosis factor α
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in menopausal and psychological symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fracture rate of ceramic FPDs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inotropic support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: length-of-stay in the intensive care unit
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: PedsQL Total Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Disease-free 5-year survival
Endpoint domain: Mortality/survival
Primary endpoint: Corrected pattern standard deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FM-100 hue error scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control of ACTH hypersecretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Composite outcome of cardiovascular death, myocardial infarction, stroke, and hospitalization for congestive heart failure
Endpoint domain: Mortality/survival
Primary endpoint: body satisfaction change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TnI concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CK-MB concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sinonasal symptom improvement (SN-5 scores)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Intubation (TTI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0,∞) of montelukast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t(1/2) of montelukast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC and C(max) of metabolite M4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete control of vertigo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reinfection rates of T. trichiura
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Improved static and dynamic balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ex vivo LDL oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acute rejection rates at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Renal function at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of patients remaining steroid-free at 1 year
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mediterranean diet adherence improvement (Gerber index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mediterranean diet adherence improvement (Kidmed test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum complement C3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-IFNα antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of IFN-induced genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dolutegravir exposure (AUC0‐∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dolutegravir exposure (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: abacavir Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abundance of Dolosigranulum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of mild respiratory tract infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Symptoms of wheezing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Bioequivalence of intravenous and oral lacosamide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total EPCO index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Course of bereavement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction of Acute Respiratory Tract Infections (ARTIs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean HF scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of short febrile episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavioral regulation (Achenbach problem scores)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postpartum assessment completion rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: final pocket depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AT burden reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total cholesterol concentration (TC) < 4.0 mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total cholesterol concentration (TC) < 4.5 mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood pressure (systolic >= 140 mmHg and/or diastolic >= 90 mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Radius bone mineral content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Net absorption and retention of Ca and P
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: adaptation percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of CSDH
Endpoint domain: Mortality/survival
Primary endpoint: mRS measurement at 6-month follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pro-collagen type III N-terminal amino peptide (PIIINP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported health-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: motor control improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal force improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virologic response to lamivudine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in physical role functioning
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Changes in ankle pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in CAT score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Better WOMAC score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Thickness of endometrium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Maximal postoperative creatinine value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: control of attention in the classroom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: regulation of social, emotional and behavioural difficulties
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall caesarean deliveries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Caesarean deliveries for non-reassuring fetal status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: GMT values for Vi antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Urinary iPF2alpha‐III concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days off active treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heartburn relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pregnancy rate per transfer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percentage of miscarriages
Endpoint domain: Adverse events/effects
Primary endpoint: satisfaction with breasts
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: sexual well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Unnecessary appendectomies
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnosis accuracy of appendicitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean M.R.D. 1 at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tolerability of tolterodine ER
Endpoint domain: Adverse events/effects
Primary endpoint: One fewer drinking day
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: intravenous fluid requirement
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Decreased plasma FFA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increased G0S2 gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of natural feeding (breastfeeding exclusively)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: three-year continuous complete remission (CCR) rate
Endpoint domain: Mortality/survival
Primary endpoint: antifungal activity against dermatophytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: fungitoxicity of itraconazole vs terbinafine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: onset and posttherapy activity duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: NRS change scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: tmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: clinical efficacy (reducing symptom scores and medication score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes